Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
21 hedge funds and large institutions have $29.1M invested in Evofem Biosciences, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $29.1M → $29.1M (-$89K)
5% less funds holding
Funds holding: 22 → 21 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPCM
Clifton Park Capital Management
Wilmington,
Delaware
|
+$5.83M |
| 2 |
Goldman Sachs
New York
|
+$282K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$114K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$53.7K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$51.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$6.36M |
| 2 |
JC
JBF Capital
Aspen,
Colorado
|
-$1.07M |
| 3 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$964K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$477K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$131K |
EVFM Hedge Fund Activity: Q1 2015 in Review
21 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2015, worth a combined $29.1M — down 0.31% from $29.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EVFM and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.
The largest buyer was Clifton Park Capital Management, opening a new position worth an estimated $5.83M. The largest seller was Tiverton Asset Management, exiting entirely with an estimated $6.36M sold.
- 21 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2015, down from 22 in Q4 2014.
- Funds reported $29.1M of Evofem Biosciences, Inc. Common Stock stock for Q1 2015, down 0.31% quarter-over-quarter.
- 5 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2015 and 6 closed out, a net change of -1 holder.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2015 was Clifton Park Capital Management, an estimated $5.83M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2015 was Tiverton Asset Management, an estimated $6.36M sold.
Based on aggregated 13F filings for Q1 2015.